Neurocrine Biosciences (1NBIX) Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1NBIX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$115.00 |
| 52 Week High | US$106.55 |
| 52 Week Low | US$106.35 |
| Beta | 0.24 |
| 1 Month Change | 4.97% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 24.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1NBIX | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 0.09% | 1.7% | 0.4% |
| 1Y | n/a | -4.8% | 16.9% |
Return vs Industry: Insufficient data to determine how 1NBIX performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1NBIX performed against the Italian Market.
Price Volatility
| 1NBIX volatility | |
|---|---|
| 1NBIX Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IT Market | 8.0% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: 1NBIX has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: Insufficient data to determine 1NBIX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,800 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
Neurocrine Biosciences, Inc. Fundamentals Summary
| 1NBIX fundamental statistics | |
|---|---|
| Market cap | €11.24b |
| Earnings (TTM) | €263.14m |
| Revenue (TTM) | €2.08b |
Is 1NBIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1NBIX income statement (TTM) | |
|---|---|
| Revenue | US$2.41b |
| Cost of Revenue | US$870.60m |
| Gross Profit | US$1.54b |
| Other Expenses | US$1.24b |
| Earnings | US$305.80m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 30, 2025
| Earnings per share (EPS) | 3.09 |
| Gross Margin | 63.91% |
| Net Profit Margin | 12.68% |
| Debt/Equity Ratio | 0% |
How did 1NBIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 04:16 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurocrine Biosciences, Inc. is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |